Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Stewart

Showing results (61-70 of 208) with videos related to

Pageof 21
Sort By:
European Journal of Haematology|November 18, 2014
Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocationChristof Scheid, Donna Reece, Meral Beksac, et al.
Transplantation|June 30, 2011
Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplantsVictor H Jimenez-Zepeda, Raymond L Heilman, Rodney A Engel, et al.
Blood|December 20, 2008
Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivoRodger E Tiedemann, Jessica Schmidt, Jonathan J Keats, et al.
The Lancet. Oncology|June 6, 2018
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 studyPhilippe Moreau, Maria-Victoria Mateos, James R Berenson, et al.
Blood|February 15, 2012
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosisJoseph R Mikhael, Steven R Schuster, Victor H Jimenez-Zepeda, et al.
Blood|February 10, 2006
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cellsSuzanne Trudel, A Keith Stewart, Eran Rom, et al.
Cancer Research|June 17, 2017
Loss of <i>FAM46C</i> Promotes Cell Survival in MyelomaYuan Xiao Zhu, Chang-Xin Shi, Laura A Bruins, et al.
The Journal of Experimental Medicine|September 24, 2004
The SH3-SAM adaptor HACS1 is up-regulated in B cell activation signaling cascadesYuan Xiao Zhu, Sally Benn, Zhi Hua Li, et al.
Blood|August 26, 2020
Targeting the Otub1/c-Maf axis for the treatment of multiple myelomaYujia Xu, Min Xu, Jiefei Tong, et al.
Annals of Internal Medicine|December 7, 2005
Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trialWilliam F Clark, A Keith Stewart, Gail A Rock, et al.
Pageof 21

Showing results (61-70 of 208) with videos related to

Sort By:
Pageof 21
European Journal of Haematology|November 18, 2014
Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocationChristof Scheid, Donna Reece, Meral Beksac, et al.
Transplantation|June 30, 2011
Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplantsVictor H Jimenez-Zepeda, Raymond L Heilman, Rodney A Engel, et al.
Blood|December 20, 2008
Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivoRodger E Tiedemann, Jessica Schmidt, Jonathan J Keats, et al.
The Lancet. Oncology|June 6, 2018
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 studyPhilippe Moreau, Maria-Victoria Mateos, James R Berenson, et al.
Blood|February 15, 2012
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosisJoseph R Mikhael, Steven R Schuster, Victor H Jimenez-Zepeda, et al.
Blood|February 10, 2006
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cellsSuzanne Trudel, A Keith Stewart, Eran Rom, et al.
Cancer Research|June 17, 2017
Loss of <i>FAM46C</i> Promotes Cell Survival in MyelomaYuan Xiao Zhu, Chang-Xin Shi, Laura A Bruins, et al.
The Journal of Experimental Medicine|September 24, 2004
The SH3-SAM adaptor HACS1 is up-regulated in B cell activation signaling cascadesYuan Xiao Zhu, Sally Benn, Zhi Hua Li, et al.
Blood|August 26, 2020
Targeting the Otub1/c-Maf axis for the treatment of multiple myelomaYujia Xu, Min Xu, Jiefei Tong, et al.
Annals of Internal Medicine|December 7, 2005
Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trialWilliam F Clark, A Keith Stewart, Gail A Rock, et al.
Pageof 21